- The Feinstein Institute currently has more than 2,000 research studies being conducted with more than 15,000 participants enrolled each year.
- Our state-of-the-art laboratories provide the infrastructure needed to conduct groundbreaking, disease-oriented research. They also house the largest genotyping facility in the state of New York.
- The Feinstein Institute ranks in the top 5th percentile of all National Institutes of Health (NIH) grants awarded to research centers.
- Our researchers are regularly published in major peer-reviewed journals such as The New England Journal of Medicine, Proceedings of the National Academy of Science, Nature and others.
- The Feinstein Institute has produced more than 200 patents in 80 distinct technologies and has generated a dozen successful biotech start-ups.
- 1963 The first genetics lab on Long Island opens at North Shore University Hospital.
- 1975 Kanti Rai, MD, and others at LIJ Medical Center create a clinical staging system for chronic lymphocytic leukemia – one of the most common forms of adult leukemia. The system is still used around the world today.
- 1980 John M. Kane, MD, and colleagues at Zucker Hillside Hospital publish a landmark study of the drug Chloral, which leads to FDA approval of the first atypical, antipsychotic drug. The study is one of the most frequently cited studies in the field of psychiatry.
- 1998 David Eidelberg, MD, and colleagues discover metabolic abnormalities in the brains of patients with Parkinson’s disease using positron emission tomography (PET) imaging, a new way to diagnose the disease.
- 1999 The North Shore-LIJ Health System establishes the North Shore-LIJ Research Institute as an independently chartered, not-forprofit research corporation. Nicholas Chiorazzi, MD, assumes role of founding president and chief executive officer.
- 2000 Kevin J. Tracey, MD, and colleagues discover the cholinergic anti-inflammatory pathway, through which the brain directly controls the immune system.
- 2005 The North Shore-LIJ Research Institute is renamed The Feinstein Institute for Medical Research in recognition of the largest single gift in the history of the health system from Bed Bath & Beyond cofounder Leonard Feinstein and his wife Susan. Kevin J. Tracey, MD, becomes president and chief executive officer.
- 2006 Betty Diamond, MD, and colleagues discover why many patients with lupus develop cognitive impairment.
- 2006 Todd Lencz, PhD, and colleagues discover a genetic mutation that predicts response to medication in first episode schizophrenia, an important step toward personalized medicine.
- 2008 The Feinstein Institute signs a collaboration agreement with the Karolinska Institute in Sweden, home of the Nobel Prize.
- 2008 The North Shore-LIJ Graduate School of Molecular Medicine changes its name to the Elmezzi Graduate School of Molecular Medicine, which received its initial charter to grant PhD degrees to recent medical school graduates in 1993.
- 2010 Christopher J. Czura, PhD, Jared Huston, MD, and colleagues discover the “neural tourniquet,” a technology that uses electrical nerve stimulation to control bleeding.
- 2011 Peter Davies, PhD and his colleagues discover that a molecule called c-Abl, which has a known role in leukemia, also has a hand in Alzheimer’s disease. The finding offers a new target for drug development that could stave off the pathological disease process.
- 2013 Peter K. Gregersen, MD, is awarded the prestigious $600,000 Crafoord Prize for his lifelong research on rheumatoid arthritis.
- 2014 As reported in the cover story of The New York Times Magazine, Feinstein Institute President Kevin J. Tracey, MD, is featured as discovering a new approach to treating disease by stimulating nerves, called bioelectronic medicine.
To view our annual report for 2014, click here.